1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

07 Mar 2024
Admin
News Article

MannKind Announces Clinical Data for Conference

MannKind announces new clinical data from INHALE-3 study; to present at International Conference on ATTD in Florence on March 6-9

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that new clinical data from the INHALE-3 study first meal challenge will be presented at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence on March 6-9. INHALE-3 study is a phase 4 US clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.

Upcoming Presentation by the Protocol Chair

Dr. Irl B. Hirsch, Professor of Medicine and Diabetes Treatment and Teaching Chair at the University of Washington and the INHALE-3 Study Protocol Chair, will provide an oral presentation focused on findings from a standardized meal challenge, including: Post-prandial glucose with inhaled insulin vs. subcutaneous rapid-acting analogue (RAA); Glucose outcomes including AUC and time to peak during the first two hours and beyond; Frequency of post-meal hypoglycemia in both groups.

MannKind Corporation on INHALE-3 Data

“We are looking forward to the first slice of INHALE-3 data being presented here that builds upon findings from our pilot ABC study shared at last year’s ATTD Conference,” said Dr. Kevin Kaiserman, senior vice president, clinical development and medical affairs for MannKind Corporation.
“With ABC and this trial, we used a higher initial conversion dose for inhaled insulin than in our current label. In the ABC study, this conversion dose produced significantly lowered post-prandial glucose levels that peaked 30 minutes sooner than standard of care.
At ATTD, we are presenting INHALE-3’s meal challenge with a much larger comparator group across treatment regimens.”

About INHALE-3

INHALE-3 is a 17-week randomized controlled trial with a 13-week extension.
The study randomly assigned participants over 18 years of age with T1D who are using MDI, an AID system, or a pump without automation to either continue their standard of care or adopt an insulin regimen of a daily basal injection plus Afrezza at mealtimes.
Both arms utilized continuous glucose monitoring to assess mealtime control and A1c levels.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!